Exposure to ozone pollution is associated with increased CVS-related hospitalizations

Published Date: 13 Mar 2023

Researchers have found in a new study that exposure to ozone pollution can increase the number of hospitalizations associated with heart disease. Also...

Read Full News

Latest News

Examining Topical Therapy for Atopic Dermatitis: Clinical Forum Perspectives

Examining Topical Therapy for Atopic Dermatitis: Clinical Forum Perspectives

Clinician FAQ: Using Remibrutinib (Rhapsido) for Symptomatic Dermographism

Clinician FAQ: Using Remibrutinib (Rhapsido) for Symptomatic Dermographism

No New Safety Signals Over 3 Years in HS With Bimekizumab: Amit Garg, MD Amit Garg, MD

Amit Garg, MD, discusses 3-year pooled BE HEARD safety data on bimekizumab in moderate to severe hidradenitis suppurativa from EADV 2026.

Q&A: Early-Career Dermatology Pearls on Defensive Patients and HS Coding

Q&A: Early-Career Dermatology Pearls on Defensive Patients and HS Coding

RLS-1496 Cream Reduces Actinic Keratosis Lesions Mary Spellman, MD

Topical GPX4 inhibitor RLS-1496 1% reduced AK lesion counts by 43.5% vs 11.3% with untreated control at Day 57, with no application site reactions.

The HCPFive: Top News for Healthcare Providers from the Week of 10/18

The HCPFive: Top News for Healthcare Providers from the Week of 10/18

Todays Updates

Q&A: Discussing 2027 GOLD Report Updates in COPD, With David Singh, MD

Q&A: Discussing 2027 GOLD Report Updates in COPD, With David Singh, MD

The HCPFive: Top News for Healthcare Providers from the Week of 11/1

The HCPFive: Top News for Healthcare Providers from the Week of 11/1

FDA Action Update, October 2026: Approval, Acceptance, and Designations Isabella Ciccone, MPH

Catch up on any of the neurology headlines you may have missed in October 2026, compiled into 1 place by the NeurologyLive® team.

T-Cell Engager Cizutamig Shows Early Efficacy Signal in Generalized Myasthenia Gravis Marco Meglio

Interim phase 1b data showed cizutamig produced rapid, sustained improvement in generalized myasthenia gravis with no cases of cytokine release syndrome.

SHASTA-3/4: Plozasiran Could Cut Acute Pancreatitis Risk by 78% Across sHTG Spectrum

SHASTA-3/4: Plozasiran Could Cut Acute Pancreatitis Risk by 78% Across sHTG Spectrum

Bimekizumab Ranks First in HS Network Meta-Analysis of 17 Trials

Bimekizumab Ranks First in HS Network Meta-Analysis of 17 Trials

Unmet Needs in HS and Emerging Oral Options, With Martina Porter, MD

Unmet Needs in HS and Emerging Oral Options, With Martina Porter, MD

Todays Updates

Q&A: Discussing 2027 GOLD Report Updates in COPD, With David Singh, MD

Q&A: Discussing 2027 GOLD Report Updates in COPD, With David Singh, MD

The HCPFive: Top News for Healthcare Providers from the Week of 11/1

The HCPFive: Top News for Healthcare Providers from the Week of 11/1

FDA Action Update, October 2026: Approval, Acceptance, and Designations Isabella Ciccone, MPH

Catch up on any of the neurology headlines you may have missed in October 2026, compiled into 1 place by the NeurologyLive® team.

T-Cell Engager Cizutamig Shows Early Efficacy Signal in Generalized Myasthenia Gravis Marco Meglio

Interim phase 1b data showed cizutamig produced rapid, sustained improvement in generalized myasthenia gravis with no cases of cytokine release syndrome.

SHASTA-3/4: Plozasiran Could Cut Acute Pancreatitis Risk by 78% Across sHTG Spectrum

SHASTA-3/4: Plozasiran Could Cut Acute Pancreatitis Risk by 78% Across sHTG Spectrum

Bimekizumab Ranks First in HS Network Meta-Analysis of 17 Trials

Bimekizumab Ranks First in HS Network Meta-Analysis of 17 Trials

Unmet Needs in HS and Emerging Oral Options, With Martina Porter, MD

Unmet Needs in HS and Emerging Oral Options, With Martina Porter, MD

Latest News

Examining Topical Therapy for Atopic Dermatitis: Clinical Forum Perspectives

Clinician FAQ: Using Remibrutinib (Rhapsido) for Symptomatic Dermographism

Amit Garg, MD, discusses 3-year pooled BE HEARD safety data on bimekizumab in moderate to severe hidradenitis suppurativa from EADV 2026.

Q&A: Early-Career Dermatology Pearls on Defensive Patients and HS Coding

Topical GPX4 inhibitor RLS-1496 1% reduced AK lesion counts by 43.5% vs 11.3% with untreated control at Day 57, with no application site reactions.

The HCPFive: Top News for Healthcare Providers from the Week of 10/18

News All Time

Fall Clinical 2026 Second Half Recap: Acne, Skin Cancer, and More

Fall Clinical 2026 Second Half Recap: Acne, Skin Cancer, and More

EADV Congress 2026: 9 Late Breakers to Know

EADV Congress 2026: 9 Late Breakers to Know

Q&A: Gene Expression Testing, Ameluz PDT, and the Psoriasis Pipeline

Q&A: Gene Expression Testing, Ameluz PDT, and the Psoriasis Pipeline

Advances in Treating High-Impact Psoriasis from EADV 2026 Christopher G. Bunick, MD, PhD

Chris Bunick, MD, PhD, discusses 52-week UnlIMMited data showing risankizumab sustained clearance, itch relief, and quality-of-life gains.

EADV Congress 2026: 5 Atopic Dermatitis Headlines to Know

EADV Congress 2026: 5 Atopic Dermatitis Headlines to Know

Q&A: Insights on New Lebrikizumab Findings for Hand and Foot Atopic Dermatitis

Q&A: Insights on New Lebrikizumab Findings for Hand and Foot Atopic Dermatitis

Nemolizumab Safety, Real-World Use in AD, With Matthias Augustin, MD Matthias Augustin, MD

An ARCADIA investigator says patients in practice match the 3-year trial results and outlines next steps for IL-31 research.

No Signal for Birth Defects in Dupilumab Pregnancy Registry, With Tina Chambers, PhD, MPH Christina Chambers, PhD, MPH

Chambers discusses final results from a 7-year dupilumab pregnancy registry showing no evidence of increased risk for major birth defects or other outcomes.

Phase 3 Ritlecitinib Results in Vitiligo, With Iltefat Hamzavi, MD Iltefat Hamzavi, MD

Iltefat H. Hamzavi, MD, discusses phase 3 Tranquillo data showing higher facial and total body repigmentation with ritlecitinib in vitiligo.

Q&A: Comorbidity Screening and Biologic Timing in HS, With Jennifer Hsiao, MD

Q&A: Comorbidity Screening and Biologic Timing in HS, With Jennifer Hsiao, MD

Is Hidradenitis Suppurativa Underdiagnosed in Male Patients?

Is Hidradenitis Suppurativa Underdiagnosed in Male Patients?

Nemolizumab Sustains AD Response at 3 Years, With Matthias Augustin, MD Matthias Augustin, MD

Up to 91% of patients reached EASI-75 at week 152 in the ARCADIA LTE, with consistent safety and gains in itch and quality of life.

Denifanstat Sustains Acne Improvement Through 52 Weeks in Phase 3 Extension

Denifanstat Sustains Acne Improvement Through 52 Weeks in Phase 3 Extension

Upadacitinib Feasible for Palmoplantar Pustulosis: David Gleeson, BM BCH David Gleeson, BM BCH

Gleeson discusses JAKPPPOT data showing the therapy met all feasibility thresholds with a markedly larger response than historic placebo in PPP.

Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism

Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism

Nemolizumab Sustains Atopic Dermatitis Skin, Itch Control Through 3 Years

Nemolizumab Sustains Atopic Dermatitis Skin, Itch Control Through 3 Years

Recommended News For You

Are Microplastics Feeding Cancer Risk?

Tissue-Free ctDNA Strongly Prognostic of Recurrence in TNBC

Journal Club: A well-accepted and safe method for soft tissue sarcoma biopsy.

'Ray of hope': New developments in the fight against various cancers.

Obesity-related cancer rising among both younger and older adults worldwide, study finds

Year in Review: Non-Small Cell Lung Cancer

Breast cancer prevention: How nurse practitioners and physician assistants can help

Recommended Articles For You

Essential Oncology Tools: Risk Assessment, Telehealth, AI, and Monitoring 

Pediatric Cancer Cell Metabolism During Development 

Preventing Treatment-Related Secondary Malignancies: Evidence-Based Strategies for Clinical Practice 

Clinical Analysis of Prostate Cancer 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Is global cancer care losing its human touch?

2.

Pressing the Sleep button could have a positive impact on cognition.

3.

Do I qualify for a cancer clinical trial?

4.

Can Alternating Venetoclax Regimens Improve AML Outcomes?

5.

Admissions, medical schools, costs, and eligibility requirements information for FNB Onco-Anesthesia.

1.

Using Node Technology to Fight Breast Cancer: A New Hope for Early Detection

2.

MASLD and Cancer Risk: Pathogenic Links and Clinical Implications Reviewed

3.

Beyond the Organs: Navigating the Era of Tissue-Agnostic Therapies in Modern Cancer Management

4.

Transformative Frameworks in Oncology for Better Care

5.

Advancing Medical Oncology: Education, Certification, Clinical Trials, and Evolving Treatment Pathways

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)

2.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII

3.

CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion

4.

Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients

5.

Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot